ROSEMONT, IL — Long Grove Pharmaceuticals, LLC, a supplier of differentiated pharmaceuticals, will bring new supply of Sodium Bicarbonate Injection, USP to the United States. Sodium Bicarbonate Injection, USP is commonly used in critical care settings yet routinely found on the drug shortages list.
"As we look at the launch of our next pharmaceutical products, our focus is always on the area of greatest need. Sodium Bicarbonate Injection supply is historically unstable, creating a challenging environment for hospitals and the patients they serve," said Peter Karas, Chief Commercial Officer at Long Grove Pharmaceuticals. "We’re excited by the opportunity to help alleviate drug shortages for this product and continue our commitment to ensuring patients have access to the medicine they need.”
Long Grove’s Sodium Bicarbonate Injection, USP is Food and Drug Administration (FDA) approved and AP rated. The company will launch its 8.4% Sodium Bicarbonate Injection, USP 50 mEq/ 50 mL vials in the second half of 2024.
Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis from severe renal disease, uncontrolled diabetes and cardiac arrest. It is most frequently used in critical care settings.
